Introduction and Objective: Hyperinsulinemia is generally regarded as a surrogate marker of insulin resistance, but high insulin levels may drive the development of metabolic dysfunction-associated steatotic liver disease (MASLD) by continuing to stimulate hepatic de novo lipogenesis (DNL) despite systemic insulin resistance. One strategy to understand the pathogenic role of hyperinsulinemia is to directly reduce high insulin levels in people with insulin resistance. Methods: We conducted a randomized, double-blind pilot Current; CorMedix. J. Wattacheril: Research Support; Current; Regeneron Pharmaceuticals Inc. Advisory Panel; Ended; AstraZeneca. Advisory Panel; Current; GlaxoSmithKline plc. Research Support; Ended; Galectin Therapeutics. H. Ginsberg: None. B. Laferrère: Consultant; Ended; Azurity. M.K. Hellerstein: Research Support; Current; Lilly, Merck & Co., Inc. Funding National Institutes of Health (K12DK133995, K23DK140614, UL1TR001873), Columbia University Department of Medicine, University of California Rausser College of Natural Resources
COOK et al. (Fri,) studied this question.